Previous Close | 5.63 |
Open | 5.61 |
Bid | 5.70 x 800 |
Ask | 6.90 x 1000 |
Day's Range | 5.22 - 5.74 |
52 Week Range | 5.22 - 36.00 |
Volume | |
Avg. Volume | 255,855 |
Market Cap | 251.14M |
Beta (5Y Monthly) | 1.57 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.87 |
Earnings Date | Aug 15, 2022 - Aug 19, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 31.40 |
Subscribe to Yahoo Finance Plus to view Fair Value for EPIX
ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal second quarter ended March 31, 2022. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the 2022 Bloom Burton & Co. Healthcare Investor Conference on Monday, May 2, 2022 at 2:30 p.m. Eastern Time.
By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update Data on First Generation Androgen Receptor N-Terminal Degrader Presented at AACR 2022 On April 8, 2022, ESSA Pharma, Inc. (NASDAQ:EPIX) announced that preclinical data for the company’s first-generation androgen receptor (AR) ANITen bAsed Chimera (ANITAC™) N-terminal domain (NTD) degraders was presented at the 2022